8-K Announcements
6Material company update
Feb 25, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Nov 6, 2025·SEC
Protagonist Therapeutics, Inc.(PTGX)Earnings, Financials & Key Ratios
PTGX•NASDAQ
$99.28
$6.21B mkt cap·Price updated May 6, 2026
AboutProtagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Show more
- Revenue$0-100.0%
- EBITDA-$158M-162.3%
- Net Income-$130M-147.3%
- EPS (Diluted)-2.05-148.5%
- ROE-20.18%-137.1%
- ROIC-21.85%-142.6%
- Debt/Equity0.02+4.4%
PTGX Key Insights
Protagonist Therapeutics, Inc. (PTGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 81 (top 19%)
- ✓Share count reduced 2.3% through buybacks
✗Weaknesses
- ✗Weak 3Y average ROE of 1.9%
- ✗Expensive at 10.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PTGX Price & Volume
Protagonist Therapeutics, Inc. (PTGX) stock price & volume — 10-year historical chart
Loading chart...
PTGX Growth Metrics
Protagonist Therapeutics, Inc. (PTGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-147.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-148.81%
Return on Capital
10 Years-34.15%
5 Years-20.44%
3 Years-2.97%
Last Year-23.96%
PTGX Recent Earnings
Protagonist Therapeutics, Inc. (PTGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (44%)
Q1 2026Latest
Feb 25, 2026EPS
$0.69
Est $0.53
-30.2%
Revenue
$7M
Est $9M
-14.9%
Q4 2025
Nov 6, 2025EPS
$0.62
Est $0.59
-5.1%
Revenue
$5M
Est $15M
-68.4%
Q3 2025
Aug 6, 2025EPS
$0.55
Est $0.53
-3.8%
Revenue
$6M
Est $8M
-34.2%
Q2 2025
May 6, 2025EPS
$0.19
Est $0.50
+62.0%
Revenue
$28M
Est $7M
+332.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.69vs $0.53-30.2% | $7Mvs $9M-14.9% |
| Q4 2025 | Nov 6, 2025 | $0.62vs $0.59-5.1% | $5Mvs $15M-68.4% |
| Q3 2025 | Aug 6, 2025 | $0.55vs $0.53-3.8% | $6Mvs $8M-34.2% |
| Q2 2025 | May 6, 2025 | $0.19vs $0.50+62.0% | $28Mvs $7M+332.0% |
Based on last 12 quarters of dataView full earnings history →
PTGX Peer Comparison
Protagonist Therapeutics, Inc. (PTGX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ACRS | 572.37M | 4.75 | -8.96 | -58.19% | -8.3% | -62.98% | ||
 ARDX | 1.75B | 7.13 | -27.42 | 22.09% | -13.58% | -38.11% | 1.27 | |
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
 SRPT | 2.28B | 21.79 | 9.31 | 52.97% | -11.25% | -20.57% | 0.88 |
Compare PTGX vs Peers
Protagonist Therapeutics, Inc. (PTGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTGX Income Statement
Protagonist Therapeutics, Inc. (PTGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20.06M | 30.93M | 231K | 28.63M | 27.36M | 26.58M | 60M | 434.43M | 0 |
| Revenue Growth % | - | 54.14% | -99.25% | 12293.07% | -4.44% | -2.84% | 125.73% | 624.05% | -100% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 20.06M▲ 0% | 30.93M▲ 54.1% | 231K▼ 99.3% | 28.63M▲ 12293.1% | 27.36M▼ 4.4% | 26.58M▼ 2.8% | 60M▲ 125.7% | 434.43M▲ 624.1% | 0▼ 100.0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | 6429.02% | 54.14% | -99.25% | 12293.07% | -4.44% | -2.84% | 125.73% | 624.05% | -100% |
| Operating Expenses | 57.96M | 73.19M | 80.75M | 93.14M | 153.2M | 157.95M | 153.65M | 181.59M | 204.14M |
| OpEx % of Revenue | 288.89% | 236.68% | 34957.58% | 325.36% | 560.01% | 594.24% | 256.09% | 41.8% | - |
| Selling, General & Admin | 11.78M | 13.7M | 15.75M | 18.64M | 27.2M | 31.74M | 33.49M | 43.46M | 44.85M |
| SG&A % of Revenue | 58.71% | 44.29% | 6817.75% | 65.1% | 99.41% | 119.4% | 55.82% | 10% | - |
| Research & Development | 46.18M | 59.5M | 65M | 75.98M | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
| R&D % of Revenue | 230.18% | 192.39% | 28139.83% | 265.42% | 460.6% | 474.83% | 200.27% | 31.8% | - |
| Other Operating Expenses | 0 | 0 | -1K | -1.48M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -37.9M▲ 0% | -42.27M▼ 11.5% | -80.52M▼ 90.5% | -64.52M▲ 19.9% | -125.84M▼ 95.1% | -131.37M▼ 4.4% | -93.65M▲ 28.7% | 252.84M▲ 370.0% | -158.13M▼ 162.5% |
| Operating Margin % | -188.89% | -136.68% | -34857.58% | -225.36% | -460.01% | -494.24% | -156.09% | 58.2% | - |
| Operating Income Growth % | -16.01% | -11.54% | -90.5% | 19.88% | -95.06% | -4.39% | 28.71% | 369.98% | -162.54% |
| EBITDA | -37.49M | -41.74M | -79.82M | -63.57M | -123.07M | -128M | -90.34M | 253.67M | -158.13M |
| EBITDA Margin % | -186.87% | -134.98% | -34553.25% | -222.05% | -449.87% | -481.56% | -150.57% | 58.39% | - |
| EBITDA Growth % | -15.9% | -11.34% | -91.22% | 20.36% | -93.6% | -4.01% | 29.42% | 380.79% | -162.34% |
| D&A (Non-Cash Add-back) | 406K | 527K | 703K | 948K | 2.77M | 3.37M | 3.31M | 826K | 0 |
| EBIT | -36.96M | -39.72M | -77.71M | -64.52M | -125.84M | -131.37M | -93.65M | 252.84M | 0 |
| Net Interest Income | 948K | 2.57M | 2.64M | 302K | 443K | 4.06M | 14.9M | 26.32M | 0 |
| Interest Income | 948K | 2.57M | 2.81M | 900K | 443K | 4.06M | 14.9M | 26.32M | 28.79M |
| Interest Expense | 0 | 0 | 169K | 598K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 940K | 2.55M | 2.64M | -329K | 294K | 3.98M | 14.7M | 26.57M | 28.82M |
| Pretax Income | -36.96M▲ 0% | -39.72M▼ 7.5% | -77.88M▼ 96.1% | -64.84M▲ 16.7% | -125.55M▼ 93.6% | -127.39M▼ 1.5% | -78.95M▲ 38.0% | 279.41M▲ 453.9% | -129.31M▼ 146.3% |
| Pretax Margin % | -184.2% | -128.45% | -33713.42% | -226.51% | -458.94% | -479.26% | -131.59% | 64.32% | - |
| Income Tax | 0 | -799K | -691K | 1.3M | 0 | 0 | 0 | 4.22M | 838K |
| Effective Tax Rate % | 0% | 2.01% | 0.89% | -2.01% | 0% | 0% | 0% | 1.51% | -0.65% |
| Net Income | -36.96M▲ 0% | -38.92M▼ 5.3% | -77.19M▼ 98.3% | -66.15M▲ 14.3% | -125.55M▼ 89.8% | -127.39M▼ 1.5% | -78.95M▲ 38.0% | 275.19M▲ 448.5% | -130.15M▼ 147.3% |
| Net Margin % | -184.2% | -125.87% | -33414.29% | -231.07% | -458.94% | -479.26% | -131.59% | 63.34% | - |
| Net Income Growth % | 0.59% | -5.32% | -98.3% | 14.3% | -89.8% | -1.47% | 38.02% | 448.54% | -147.29% |
| Net Income (Continuing) | -36.96M | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.95M | 275.19M | -130.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.09▲ 0% | -1.74▲ 16.7% | -2.98▼ 71.3% | -1.92▲ 35.6% | -2.65▼ 38.0% | -2.52▲ 4.9% | -1.39▲ 44.8% | 4.23▲ 404.3% | -2.05▼ 148.5% |
| EPS Growth % | 63.46% | 16.75% | -71.26% | 35.57% | -38.02% | 4.91% | 44.84% | 404.32% | -148.46% |
| EPS (Basic) | -2.09 | -1.74 | -2.98 | -1.92 | -2.65 | -2.52 | -1.39 | 4.47 | -2.05 |
| Diluted Shares Outstanding | 17.69M | 22.36M | 25.89M | 34.4M | 46.32M | 49.04M | 56.76M | 65.08M | 63.57M |
| Basic Shares Outstanding | 17.69M | 22.36M | 25.89M | 34.4M | 46.32M | 49.04M | 56.76M | 61.57M | 63.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PTGX Balance Sheet
Protagonist Therapeutics, Inc. (PTGX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 150.95M | 137.5M | 145.31M | 315.61M | 340.74M | 243.08M | 355.58M | 591.64M | 577.57M |
| Cash & Short-Term Investments | 144M | 128.85M | 133.02M | 305.81M | 326.9M | 237.35M | 341.62M | 418.91M | 567.36M |
| Cash Only | 106.03M | 82.23M | 33.01M | 117.36M | 123.67M | 125.74M | 186.73M | 97.25M | 128.39M |
| Short-Term Investments | 37.97M | 46.62M | 100.01M | 188.45M | 203.24M | 111.61M | 154.89M | 321.66M | 438.97M |
| Accounts Receivable | 1.82M | 4.59M | 6.75M | 3.82M | 5.33M | 52K | 10.33M | 168.49M | 0 |
| Days Sales Outstanding | 33.04 | 54.14 | 10.67K | 48.72 | 71.15 | 0.71 | 62.85 | 141.56 | - |
| Inventory | -8.75M | 2.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 10.24M | -205K | 754K | 10K | 0 | 0 | 0 | 0 | 10.21M |
| Total Non-Current Assets | 12.79M | 1.97M | 9.61M | 8.86M | 6.96M | 4.85M | 2.37M | 153.08M | 90.61M |
| Property, Plant & Equipment | 879K | 861K | 7.72M | 6.41M | 6.73M | 4.63M | 2.15M | 12.61M | 11.69M |
| Fixed Asset Turnover | 22.82x | 35.92x | 0.03x | 4.46x | 4.06x | 5.75x | 27.92x | 34.46x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 11.46M | 450K | 0 | 2M | 0 | 0 | 0 | 140.25M | 0 |
| Other Non-Current Assets | 450K | 450K | 450K | 450K | 225K | 225K | 225K | 225K | 78.92M |
| Total Assets | 163.73M▲ 0% | 139.47M▼ 14.8% | 154.92M▲ 11.1% | 324.47M▲ 109.4% | 347.69M▲ 7.2% | 247.93M▼ 28.7% | 357.95M▲ 44.4% | 744.73M▲ 108.1% | 668.19M▼ 10.3% |
| Asset Turnover | 0.12x | 0.22x | 0.00x | 0.09x | 0.08x | 0.11x | 0.17x | 0.58x | - |
| Asset Growth % | 74.2% | -14.82% | 11.07% | 109.45% | 7.16% | -28.69% | 44.38% | 108.05% | -10.28% |
| Total Current Liabilities | 42.55M | 26.16M | 35.41M | 40.24M | 44.02M | 31.18M | 21.27M | 47.4M | 45.44M |
| Accounts Payable | 1.26M | 5.71M | 2.79M | 3.08M | 1.6M | 3.64M | 772K | 1.61M | 5.34M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.28M |
| Deferred Revenue (Current) | 31.75M | 8.22M | 19M | 17.21M | 2.5M | 69K | 0 | 18.89M | 9.55M |
| Other Current Liabilities | 6.83M | 9.5M | 4.64M | 6.41M | 7.13M | 4.97M | 6.79M | 23.69M | 28.27M |
| Current Ratio | 3.55x | 5.26x | 4.10x | 7.84x | 7.74x | 7.80x | 16.71x | 12.48x | 12.71x |
| Quick Ratio | 3.75x | 5.17x | 4.10x | 7.84x | 7.74x | 7.80x | 16.71x | 12.48x | 12.71x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 547K | 799K | 39.55M | 4.62M | 3.66M | 1.14M | 0 | 22.03M | 8.04M |
| Long-Term Debt | 0 | 0 | 9.79M | 0 | 0 | 0 | 0 | 0 | 8.04M |
| Capital Lease Obligations | 0 | 0 | 5.96M | 4.5M | 3.66M | 1.14M | 0 | 10.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 221K | 0 | 0 |
| Other Non-Current Liabilities | 547K | 799K | 0 | 121K | 0 | 0 | -221K | 11.68M | 0 |
| Total Liabilities | 43.1M | 26.96M | 74.95M | 44.86M | 47.67M | 32.32M | 21.27M | 69.43M | 53.48M |
| Total Debt | 0 | 0 | 17.01M | 5.96M | 5.86M | 3.66M | 1.14M | 10.87M | 10.32M |
| Net Debt | -106.03M | -82.23M | -15.99M | -111.4M | -117.81M | -122.09M | -185.59M | -86.38M | -118.07M |
| Debt / Equity | - | - | 0.21x | 0.02x | 0.02x | 0.02x | 0.00x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.04x | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.34x | - |
| Interest Coverage | - | - | -476.46x | -107.89x | - | - | - | - | - |
| Total Equity | -101.55M▲ 0% | -140.47M▼ 38.3% | 79.96M▲ 156.9% | 279.61M▲ 249.7% | 300.02M▲ 7.3% | 215.61M▼ 28.1% | 336.68M▲ 56.2% | 675.29M▲ 100.6% | 614.71M▼ 9.0% |
| Equity Growth % | -57.22% | -38.33% | 156.92% | 249.66% | 7.3% | -28.14% | 56.15% | 100.58% | -8.97% |
| Book Value per Share | -5.74 | -6.28 | 3.09 | 8.13 | 6.48 | 4.40 | 5.93 | 10.38 | 9.67 |
| Total Shareholders' Equity | -101.55M | -140.47M | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M | 675.29M | 614.71M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K |
| Retained Earnings | -101.55M | -140.47M | -217.66M | -283.81M | -409.36M | -536.75M | -615.71M | -340.52M | -470.67M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6K | -233K | -221K | 28K | -299K | -359K | -105K | -82K | 641K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PTGX Cash Flow Statement
Protagonist Therapeutics, Inc. (PTGX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.87M | -49.95M | -41.53M | -72.48M | -107.86M | -108.14M | -70.24M | 184.15M | 57.67M |
| Operating CF Margin % | 19.3% | -161.51% | -17977.06% | -253.19% | -394.29% | -406.82% | -117.06% | 42.39% | - |
| Operating CF Growth % | 112.92% | -1389.95% | 16.86% | -74.55% | -48.81% | -0.25% | 35.05% | 362.19% | -68.68% |
| Net Income | -36.96M | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.95M | 275.19M | 0 |
| Depreciation & Amortization | 406K | 527K | 2.5M | 2.56M | 2.77M | 3.37M | 3.31M | 2.9M | 0 |
| Stock-Based Compensation | 4.24M | 6.92M | 8.35M | 7.9M | 16.39M | 24.2M | 29.29M | 37.55M | 45.97M |
| Deferred Taxes | 0 | -658K | -775K | 1.44M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 625K | 206K | -557K | 781K | 1.83M | -549K | -4.38M | -8.88M | 11.7M |
| Working Capital Changes | 35.56M | -18.02M | 26.14M | -19.02M | -3.31M | -7.77M | -19.51M | -122.61M | 0 |
| Change in Receivables | -1.82M | -2.77M | -757K | 3.34M | -915K | 4.24M | 0 | -155M | 0 |
| Change in Inventory | 5.53M | 3.85M | 757K | -3.34M | 915K | -4.24M | 0 | 0 | 0 |
| Change in Payables | 91K | 4.43M | -3M | 309K | -1.39M | 2.04M | -2.93M | 842K | 0 |
| Cash from Investing | 15.82M | 2.21M | -53.71M | -90.97M | -15.86M | 91.47M | -39.26M | -299.48M | -49.33M |
| Capital Expenditures | -666K | -486K | -967K | -471K | -1.1M | -795K | -609K | -1.35M | 0 |
| CapEx % of Revenue | 3.32% | 1.57% | 418.61% | 1.65% | 4.02% | 2.99% | 1.01% | 0.31% | - |
| Acquisitions | 0 | 0 | 52.74M | 90.49M | 14.76M | -91.47M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 16.49M | 2.7M | -52.74M | -90.49M | -14.76M | 91.47M | 0 | 0 | -49.33M |
| Cash from Financing | 65.55M | 24.11M | 46.04M | 247.63M | 129.92M | 18.84M | 170.48M | 25.85M | 22.86M |
| Debt Issued (Net) | 0 | 0 | 9.77M | -10.52M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.01M | 934K | 1.78M | 2.79M | 6.09M | 4.29M | 38.38M | -600K | 22.86M |
| Net Change in Cash | 85.39M▲ 0% | -23.8M▼ 127.9% | -49.23M▼ 106.9% | 84.35M▲ 271.4% | 6.07M▼ 92.8% | 2.08M▼ 65.8% | 60.98M▲ 2833.3% | -89.48M▼ 246.7% | 0▲ 100.0% |
| Free Cash Flow | 3.21M▲ 0% | -50.43M▼ 1673.1% | -42.49M▲ 15.7% | -72.95M▼ 71.7% | -108.97M▼ 49.4% | -108.93M▲ 0.0% | -70.84M▲ 35.0% | 182.8M▲ 358.0% | 57.67M▼ 68.5% |
| FCF Margin % | 15.98% | -163.08% | -18395.67% | -254.84% | -398.31% | -409.81% | -118.08% | 42.08% | - |
| FCF Growth % | 110.56% | -1673.08% | 15.74% | -71.68% | -49.36% | 0.03% | 34.96% | 358.02% | -68.45% |
| FCF per Share | 0.18 | -2.26 | -1.64 | -2.12 | -2.35 | -2.22 | -1.25 | 2.81 | 0.91 |
| FCF Conversion (FCF/Net Income) | -0.10x | 1.28x | 0.54x | 1.10x | 0.86x | 0.85x | 0.89x | 0.67x | -0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PTGX Key Ratios
Protagonist Therapeutics, Inc. (PTGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -96.53% | -36.79% | -43.32% | -49.41% | -28.59% | 54.39% | -20.18% |
| Return on Invested Capital (ROIC) | - | - | - | -94.41% | -41.68% | -53.87% | -71.47% | -57.43% | 51.25% | -21.85% |
| Gross Margin | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - |
| Net Margin | - | -184.2% | -125.87% | -33414.29% | -231.07% | -458.94% | -479.26% | -131.59% | 63.34% | - |
| Debt / Equity | - | - | - | 0.21x | 0.02x | 0.02x | 0.02x | 0.00x | 0.02x | 0.02x |
| Interest Coverage | - | - | - | -476.46x | -107.89x | - | - | - | - | - |
| FCF Conversion | 0.81x | -0.10x | 1.28x | 0.54x | 1.10x | 0.86x | 0.85x | 0.89x | 0.67x | -0.44x |
| Revenue Growth | - | - | 54.14% | -99.25% | 12293.07% | -4.44% | -2.84% | 125.73% | 624.05% | -100% |
PTGX SEC Filings & Documents
Protagonist Therapeutics, Inc. (PTGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PTGX Frequently Asked Questions
Protagonist Therapeutics, Inc. (PTGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Protagonist Therapeutics, Inc. (PTGX) saw revenue decline by 100.0% over the past year.
Protagonist Therapeutics, Inc. (PTGX) reported a net loss of $130.1M for fiscal year 2025.
Dividend & Returns
Protagonist Therapeutics, Inc. (PTGX) has a return on equity (ROE) of -20.2%. Negative ROE indicates the company is unprofitable.
Protagonist Therapeutics, Inc. (PTGX) generated $57.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More PTGX
Protagonist Therapeutics, Inc. (PTGX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates